Leukemia Clinical Trials in Houston

Showing 181-200 of 782 trials

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

NCT05464836

To learn if the combination of 2 study drugs, CB-103 and venetoclax, can help to control T-cell acute lymphoblastic leukemia (T-ALL) or T-cell lymphoblastic leukemia (T-LBL) in adolescent and young adult patients

Leukemia, LymphoblasticLeukemia

M.D. Anderson Cancer Center2 participantsStarted Apr 2023

Houston, Texas, United States

ACTIVE_NOT_RECRUITINGPHASE1< 1 mile

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

NCT03740334

This research study is evaluating a drug called ribociclib (LEE011) given in combination with everolimus and other standard of care chemotherapy drugs as a possible treatment for relapsed or refractory ALL. The names of the drugs involved in this study are: * ribociclib * everolimus * dexamethasone

Acute Lymphoblastic Leukemia ALL

Dana-Farber Cancer Institute45 participantsStarted Jan 2019

Aurora, Colorado, United States • Wilmington, Delaware, United States • Atlanta, Georgia, United States +9 more locations

Phase II Study to Evaluate Safety and Efficacy of CB-103 With Venetoclax in Adolescent and Young Adult Patients With Relapsed/Refractory T-ALL or T-LBL

Ribociclib in Combination With Everolimus and Dexamethasone in Relapsed ALL

Leukemia Trials in Other Cities

Venetoclax With Ibrutinib or Acalabrutinib in Pts. With High-risk CLL

A Phase I/II Study of Gilteritinib and Momelotinib for Patients With Relapsed or Refractory FLT3-Mutated Acute Myeloid Leukemia

A Phase III Study of Ceralasertib Plus Durvalumab Versus Docetaxel in Patients With Non Small Cell Lung Cancer (NSCLC) Whose Disease Progressed On or After Prior Anti PD (L)1 Therapy And Platinum Based Chemotherapy

Study of TNG260 and an Anti-PD Antibody in STK11 Mutated Solid Tumors

An Open-label Study of Encorafenib + Binimetinib in Patients With BRAFV600-mutant Non-small Cell Lung Cancer

Study BT5528-100 in Patients With Advanced Solid Tumors Associated With EphA2 Expression

Safety and Tolerability of TNG908 in Patients With MTAP-deleted Solid Tumors

Trivalent CAR-T Cell in Acute B-Lineage Leukemia (TRICAR-ALL)

A Study of Zilovertamab Vedotin (MK-2140/VLS-101) in Participants With Solid Tumors (MK-2140-002)

Study of CHS-388 (Formerly Known as SRF388) in Patients With Advanced Solid Tumors

Phase I/II Study of Autologous T Cells to Express T-Cell Receptors (TCRs) in Subjects With Solid Tumors

Risk Reducing Salpingectomy With Delayed Oophorectomy as an Alternative to Risk- Reducing Salpingo-oophorectomy in High Risk-Women to Assess the Safety of Prevention - US Cohort Study

Study of AVZO-021 in Patients With Advanced Solid Tumors

Comparison of the Treatments of Obinutuzumab + Venetoclax Versus Obinutuzumab + Chlorambucil in Patients With Chronic Lymphocytic Leukemia

Talazoparib and Low-Dose Temozolomide in Treating Participants With Relapsed or Refractory Extensive-Stage Small Cell Lung Cancer

Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With Pembrolizumab for Treatment of Recurrent (Non-small Cell) Lung Cancer

A Study to Find Out How Safe REGN5668 is and How Well it Works In Adult Women When Given With Either Cemiplimab, or Cemiplimab + Fianlimab, or Ubamatamab

Tafasitamab and Zanubrutinib for the Treatment of Patients With Newly Diagnosed Chronic Lymphocytic Leukemia or Small Lymphocytic Lymphoma, TaZA CLL Study

Other Conditions in Houston